source
- EnGene shares tumble 80% after Phase 2 bladder cancer data raise safety concernsEnGene, a Canadian biotech firm, released updated Phase 2 results for its experimental therapy aimed at a specific group of bladder cancer patients. The company said the new data fell short of expe…
- Blackstone invests $250 million in Anagram to address cystic fibrosis complicationBlackstone Life Sciences announced a $250 million investment in Anagram, a biotech focused on cystic fibrosis complications. The funding is part of one of the largest private investment funds in t…